Thermo Fisher Scientific Inc

As of June 30, 2026, Thermo Fisher Scientific Inc. Shs Unsponsored Canadian Depoitary Receipt Hedged Reg S carries a market capitalization of 263.06B, placing it among publicly traded companies globally. Its enterprise value stands at 317.86B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Thermo Fisher Scientific Inc. Shs Unsponsored Canadian Depoitary Receipt Hedged Reg S's next confirmed earnings release is scheduled for February 4, 2027.

As of June 30, 2026, Thermo Fisher Scientific Inc. Shs Unsponsored Canadian Depoitary Receipt Hedged Reg S has 14.66B shares outstanding.

As of June 30, 2026, Thermo Fisher Scientific Inc. Shs Unsponsored Canadian Depoitary Receipt Hedged Reg S trades at a trailing price-to-earnings ratio of 26.93. The price-to-sales ratio is 4.05, and the price-to-book ratio stands at 3.52.

As of June 30, 2026, Thermo Fisher Scientific Inc. Shs Unsponsored Canadian Depoitary Receipt Hedged Reg S trades at an EV/EBITDA multiple of 20.20 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 4.83 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 27.49 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Thermo Fisher Scientific Inc. Shs Unsponsored Canadian Depoitary Receipt Hedged Reg S trades at an EV/FCF ratio of 25.83, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 317.86B versus a market cap of 263.06B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Thermo Fisher Scientific Inc. Shs Unsponsored Canadian Depoitary Receipt Hedged Reg S maintains a current ratio of 1.55, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 80.57, indicating elevated leverage, while an interest coverage ratio of 7.56 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Thermo Fisher Scientific Inc. Shs Unsponsored Canadian Depoitary Receipt Hedged Reg S posted a return on equity (ROE) of 13.50, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 8.30 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 6.50, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 9.16, useful for judging operating efficiency across full business cycles. The company generates approximately 526,084.12 in revenue per employee across its workforce of 125,000.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.90 indicates how many times Thermo Fisher Scientific Inc. Shs Unsponsored Canadian Depoitary Receipt Hedged Reg S sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Thermo Fisher Scientific Inc. Shs Unsponsored Canadian Depoitary Receipt Hedged Reg S recorded 847.27M in income tax expense. That works out to an effective tax rate of 7.82, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 10.84B, leaving 9.89B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Thermo Fisher Scientific Inc. Shs Unsponsored Canadian Depoitary Receipt Hedged Reg S's stock has gained approximately 16.68% over the past 52 weeks. The 50-day moving average sits at 22.82, while the 200-day moving average is 19.81.

Over the twelve months ended June 30, 2026, Thermo Fisher Scientific Inc. Shs Unsponsored Canadian Depoitary Receipt Hedged Reg S generated 65.76B in revenue and converted that into 9.89B in net income, yielding earnings per share of 0.67. EBITDA reached 15.74B, while operating income came in at 12.03B.

As of June 30, 2026, Thermo Fisher Scientific Inc. Shs Unsponsored Canadian Depoitary Receipt Hedged Reg S holds 5.77B in cash and equivalents against 60.39B in total debt, resulting in a net debt position of 54.62B. Total book value stands at 74.76B, with working capital of 11.77B providing operational flexibility.

Thermo Fisher Scientific Inc. Shs Unsponsored Canadian Depoitary Receipt Hedged Reg S produced 12.79B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -2.41B in capital expenditures, free cash flow totaled 10.39B - equivalent to 0.70 per share.

Over the twelve months ended June 30, 2026, Thermo Fisher Scientific Inc. Shs Unsponsored Canadian Depoitary Receipt Hedged Reg S posted a gross margin of 40.80, reflecting its pricing power and cost economics. The operating margin of 18.29 and net profit margin of 15.04 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Thermo Fisher Scientific Inc. Shs Unsponsored Canadian Depoitary Receipt Hedged Reg S paid dividends of 0.06 per share. The dividend payout ratio of 9.44 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 3.90, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -1.30, meaning Thermo Fisher Scientific Inc. Shs Unsponsored Canadian Depoitary Receipt Hedged Reg S raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Thermo Fisher Scientific Inc. Shs Unsponsored Canadian Depoitary Receipt Hedged Reg S has an Altman Z-Score of 6.15, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.